The Zepto ® Capsulotomy System was developed for Mynosys by the Zepto Product Team. Zepto is a registered trademark of Mynosys Cellular Devices, Inc.

John Hendrick, President and CEO

Mr. Hendrick has over three decades of executive experience, building both early stage medical device companies as well as large divisions in medical device corporations. During his career, Mr. Hendrick has participated in the development, manufacture and commercialization of products in Cardiology, Urology, Orthopedics and Ophthalmology.  Prior to his current position, Mr.Hendrick was the CEO of NeoVista Inc. a company in the field of Age Related Macular Degeneration.  Prior to Neovista, John created the Medical Division of Sanmina-Sci, which during his tenure, became the largest medical device contract manufacturer in world. Mr. Hendrick has also previously held executive positions at Allergan Medical Optics, Baxter and American Hospital Supply.

Patrick Lydon, OD; Vice President, Clinical Affairs, Sales & Marketing

Dr. Lydon began his career in ophthalmology first as a private practice optometrist and later as Director of Doctor Relations with Pearle Vision Care.  In this role his responsibilities included peer review, clinical quality assurance and business development.  Subsequently, he assumed entrepreneurial leadership roles in Sales, Clinical Training and Marketing at Cole Managed Vision, Genentech, NeoVista, AcuFocus and Refocus.  Pat joined Mynosys in 2016 and has been leading the commercial launch of Zepto.   When time permits, Pat also plays guitar in two bands, scuba dives and attempts to golf.

Taoufiq Jellal, Vice President EURMEA Sales and Marketing

Taoufiq Jellal (known as TJ) has been our Vice President Sales & Marketing for Europe, Middle East and Africa since August 2017. Mr. Jellal served as General Manager EUMEA at Transcend Medical and successfully contributed to the acquisition of Transcend by Novartis/Alcon. Prior to Transcend he served as Vice President of Sales for EUMEA at Optonol, Inc. Mr. Jellal has extensive sales and marketing experience in ophthalmology in Europe the Middle East and Africa, having started his career in ophthalmology in 1989. He has served in various leading sales and marketing positions in the ophthalmic field for almost 30 years. Mr. Jellal held the positions of International Sales Director at Second Sight; Business Unit Manager, Surgical, at Alcon Pharmaceuticals, and General Manager EMEA at TearScience and NeoVista. He has served in international positions in the following companies: Iridex Corporation, Heidelberg Engineering, Allergan and Storz. He has a Master degree in Sociology from the University of Paris, France and an MBA from the International Business School in Hamburg, Germany. Mr. Jellal is father of twin sons, an amateur golfer and a convinced epicurean.

Jim Conroy M.D., Clinical Training and Marketing Specialist

Dr. Jim Conroy is a Board-Certified Family Practice physician and a Fellow of the American Academy of Family Practice, with certification in Sports Medicine.  He has extensive administrative experience including years as Chief of Family Practice and Chief of Prevention at Santa Teresa Medical Center in San Jose, CA.  Subsequently, his later career with Kaiser took him to North Carolina as Senior Lead, with operations management responsibility.   Dr. Conroy retired from The Permanente Medical Group after 29 years prior to joining Mynosys. Dr. Conroy received two degrees from MIT and performed research work at the Massachusetts General Hospital, before enrolling at the University of Cincinnati Medical School.

NEWS

28 Jun Streamlined method for anchoring cataract surgery and intraocular lens centration on the patient’s visual axis In this article, Dr. Vance Thompson describes "an intraoperative ... read more ›
12 Jun Mynosys Announces Significantly Less Posterior Capsular Opacification in Patients After Zepto® Capsulotomy FREMONT, CALIF. (PRWEB) JUNE 06, 2018 Mynosys Cellular Devices ... read more ›
31 May Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018 Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” ... read more ›

FEATURED VIDEO